Irreversible inhibitors of adenosine receptors

Details Irreversible inhibitors of adenosine receptors Irreversible inhibitors of adenosine receptors

1994-03-28

1996-08-13

Grumbling, Matthew V.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514266, 514263, 514265, 536 2762, 544277, 544273, A61K 3152, A61K 3170, C07D47334, C07H 1702

Patent

active

055456278

ABSTRACT:
Irreversible ligands for adenosine receptors are derived from agonist and antagonist functionalized congeners which contain electrophilic acylating and alkylating groups for reaction at nucleophilic residues of adenosine receptors. The ligands are based on 8-aryl-substituted xanthines as antagonists and on N.sup.6 -substituted adenosine as agonists.

REFERENCES:
patent: 2840559 (1958-06-01), Krantz et al.
patent: 3317533 (1967-05-01), De Ridder
patent: 3480424 (1969-11-01), Lemin
patent: 3530161 (1970-09-01), Hull
patent: 3641010 (1972-02-01), Schweiss et al.
patent: 3660380 (1972-05-01), Schmidt et al.
patent: 4213984 (1980-07-01), Schmidt et al.
patent: 4213985 (1980-07-01), Schmidt et al.
patent: 4218396 (1980-08-01), Haugwitz et al.
patent: 4233303 (1980-11-01), Bergstrand et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4381301 (1983-04-01), Rainer
patent: 4452788 (1984-06-01), Bristol et al.
patent: 4456687 (1994-06-01), Green
patent: 4469698 (1984-09-01), Philipposian et al.
patent: 4472572 (1994-09-01), Shizuya
patent: 4514405 (1985-04-01), Irmscher et al.
patent: 4546182 (1985-10-01), Kjellin et al.
patent: 4568676 (1986-02-01), Smith
patent: 4593095 (1986-06-01), Snyder et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4820709 (1989-04-01), Hofer
patent: 4879296 (1989-11-01), Daluge et al.
patent: 5098996 (1992-03-01), Jacobson et al.
patent: 5280015 (1994-01-01), Jacobson et al.
patent: 5284834 (1994-02-01), Jacobson et al.
Barraco et al., "Depression of locomotor activity following bilateral injections of adenosine analogs into the striatum of mice," Med. Sci. Res., 15, 421-422 (1987).
Baumgold et al., "Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding," Biochem. Pharmacol., 43, 889-894 (1992).
Brodie et al., "Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action," Brain Research, 415, 323-330 (1987).
Bruns et al., "Characterization of the A.sub.2 adenosine receptor labeled by [.sup.3 H]NECA in rat striatal membranes," Molecular Pharmacol., 29, 331-346 (1986).
Bruns et al., "Adenosine receptors in brain membranes: binding of N.sup.6 -cyclohexyl[.sup.3 H]adenosine and 1,3-diethyl-8 [.sup.3 H]phenylxanthine," Proc. Natl. Acad. Sci. USA, 77, 5547-5551 (1980).
Busto et al., "Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury," J. Cerebral Blood Flow and Metabolism, 7, 729-738 (1987).
Daly et al, "1,3-dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A.sub.1 - and A.sub.2 -adenosine receptors," J. Med. Chem., 28, 487-492 (1985).
De et al., "Differential distribution of A3 receptor in rat brain," Society for Neuroscience Abstracts, 19, 42.11 (1993).
Donaruma et al., "Polymeric ligands. 9. Oxidation-reduction properties of some polymeric thiosemicarbazides containing copper ions," Macromolecules, 12, 435-438 (1979).
Evoniuk et al., "Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl)theophylline," J. Pharmacol. Exp. Ther., 240, 428-432 (1987).
Hutchison et al., "2-(arylalkylamino)adenosin-5'-uranomides: a new class of highly selective adenosine A.sub.2 receptor ligands," J. Med. Chem., 33, 1919-1924 (1990).
Ijzerman et al., "Molecular modeling of adenosine receptors. I. The ligand binding site on the A.sub.1 receptor," Drug Design and Discovery, 9, 49-67 (1992).
Jacobson et al., "8-(3-Chlorostyryl)caffeine (CSC) is a selective A.sub.2 -adenosine antagonist in vitro and in vivo," FEBS, 323, 141-144 (1993).
Jacobson et al., "Synthesis and biological activity of N.sup.6 -(p-sulfophenyl)alkyl and N.sup.6 -sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists," J. Med. Chem., 35, 4143-4149 (1992).
Jacobson et al., "Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential," J. Med. Chem., 35, 407-422 (1992).
Jacobson et al., "Novel therapeutics acting via purine receptors," Biochem. Pharmacol., 41, 1399-1410 (1990).
Jacobson et al., "Electrophillic derivatives of purines as irreversible inhibitors of A.sub.1 adenosine receptors," J. Med. Chem., 32, 1043-1051 (1989).
Jacobson et al., "Molecular probes for extracellular adenosine receptors," Biochem. Pharmacol., 36, 1697-1707 (1987).
Jacobson et al., "[.sup.3 H]Xanthine amine congener of 1,3-dipropyl-8-phenylzanthine: an antagonist radioligand for adenosine receptors," Proc. Natl. Acad. Sci. USA, 83, 4089-4091 (1986).
Jacobson et al., "Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors," J. Med. Chem., 28, 1334-1340 (1985).
Karton et al., "Muscarinic receptor subtype-selectivity of pirenzipine derivatives," Abstract from Society for Neuroscience 1990 Annual Meeting, St. Louis, Missouri (1990).
Lee et al., "Improvement of cold tolerance by selective A.sub.1 adenosine receptor antagonists in rats," Pharmacol. Biochem. & Behavior, 37, 107-112 (1990).
Meyerhof et al., "Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis," FEBS Lett., 284, 155-160 (1991).
Minamisawa et al., "Preservation of brain temperature during ischemia in rats," Stroke, 21, 758-764 (1990).
Nakata, "Purification of A.sub.1 adenosine receptor from rat brain membranes," J. Biol. Chem., 264, 16545-16551 (1989).
Nikodijevic et al., "Characterization of the locomotor depression produced by an A.sub.2 -selective adenosine agonist," FEBS, 261, 67, (1990).
Olsson et al., "N.sup.6 -substituted N-alkyladenosine-5'-uranomides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors," J. Med. Chem., 29, 1683-1689 (1986).
Ramkumar et al., "The A.sub.3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells," J. Biol. Chem., 268, 16887-16890 (1993).
Reddington et al., "An A.sub.1 -adenosine receptor, characterized by (3H)cyclohexyladenosine binding, mediates the depression of evoked potentials in a rat hippocampal slice preparation," Neurosci. Lett., 28, 275-279 (1982).
Schingnitz et al., "Selective A.sub.1 -antagonists for treatment of cognitive deficits," Nucleosides & Nucleotides, 10, 1067-1076 (1991).
Seale et al., "3,7-dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs," Life Sciences, 43 1671-1684 (1988).
Stiles et al., "High affinity acylating antagonists for the A.sub.1 adenosine receptor: identification of binding subunit," Mol. Pharmacol., 34, 724-728 (1988).
Ukena et al., "Definition of subclasses of adenosine receptors associated with adenylate cyclase: interaction of adenosine analogs with inhibitory A.sub.1 receptors and stimulatory A.sub.2 receptors," Canadian J. Physiol. Pharmacol., 65, 365-376 (1987).
van Bergen et al., "A.sub.3 receptors: structure-activity relationships and molecular modeling," Abstract from American Chemical Society Meeting, Chicago, Illinois (Aug. 1993).
van Galen et al., "Adenosine A.sub.1 and A.sub.2 receptors: structure-function relationships," Med. Res. Reviews, 12, 423-471 (1992).
van Galen et al., "Xanthine-7-ribosides as adenosine receptor antagonists: further evidence for adenosine's anti mode of binding," Nucleosides & Nucleotides, 10, 1191-1193 (1991).
van Galen et al., "1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists," J. Med. Chem., 34, 1202-1206 (1991).
van Galen et al., "Xanthine-7-ribosides as adenosine receptor antagonists: further evidence for adenosine's anti mode of binding," Nucleosides & Nucleotides, 10, 1191-1193, (1991).
van Galen et al., "Xanthine-7-ribosides as adenosine A.sub.1 receptor antagonists: further evidence for adenosine's anti mode of binding," Nucleosides & Nucleotides, 9, 275-291 (1990).
Vannucci et al, "A.sub.1 -adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats," Am. J. Physiol., 257, E871-E878 (1989).
Von Lubitz et al., "A novel treatment of global cerebral schaemia w

Affiliated with

Also associated with

Rating

Irreversible inhibitors of adenosine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Irreversible inhibitors of adenosine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Irreversible inhibitors of adenosine receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1047992